Dr. Ruth Ben Yakar
BiondVax Pharmaceuticals Ltd.
Dr. Ruth Ben Yakar has over 22 years of experience in the biomedical field, including 15 years of management in the biotech industry, leading diverse corporate, business, operational, financial, clinical development, and research activities. Dr. Ben Yakar serves as the CEO of BioSight , a clinical-phase biotech company, a Director at SHL Telemedicine and Cellect Biomed, a business consultant to several biomed companies, and a guest lecturer at Lahav, the Recannati Business School of Tel-Aviv University. She formerly served as the CEO of the biotech companies Procognia and Thrombotech, as a Director at IATI, as the Chief Business Officer of YEDA, the technology transfer company of the Weizmann Institute of Science, and as a Vice President in several Biotech companies. Dr. Ben Yakar holds a PhD Cum Laude from the Weizmann Institute of Science.